Precision BioSciences Inc. [NASDAQ: DTIL] loss -11.89% or -1.38 points to close at $10.23 with a heavy trading volume of 2329855 shares. The company report on November 25, 2020 that Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference.
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, announced that its Chief Scientific Officer, Derek Jantz, Ph.D., will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020.
This fireside chat has been pre-recorded and is now available for registered attendees via the Piper Sandler conference site until December 3. It is also available on Precision’s website, www.PrecisionBiosciences.com in the Investors and Media section under Events and Presentations.
It opened the trading session at $11.43, the shares rose to $11.58 and dropped to $9.2501, the range by which the price of stock traded the whole day. The daily chart for DTIL points out that the company has recorded 43.48% gains over the past six months. However, it is still -129.89% lower than its most recent low trading price.
If we look at the average trading volume of 702.33K shares, DTIL reached to a volume of 2329855 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Precision BioSciences Inc. [DTIL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DTIL shares is $17.71 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DTIL stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Precision BioSciences Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 27, 2020. While these analysts kept the previous recommendation, Goldman raised their target price from $24 to $7. The new note on the price target was released on April 03, 2020, representing the official price target for Precision BioSciences Inc. stock. Previously, the target price had yet another raise to $21, while Stifel analysts kept a Buy rating on DTIL stock.
The Average True Range (ATR) for Precision BioSciences Inc. is set at 0.88, with the Price to Sales ratio for DTIL stock in the period of the last 12 months amounting to 23.55. The Price to Book ratio for the last quarter was 8.39, with the Price to Cash per share for the same quarter was set at 2.06.
Trading performance analysis for DTIL stock
Precision BioSciences Inc. [DTIL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.12. With this latest performance, DTIL shares gained by 58.60% in over the last four-week period, additionally plugging by 43.48% over the last 6 months – not to mention a drop of -38.52% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DTIL stock in for the last two-week period is set at 55.10, with the RSI for the last a single of trading hit 48.53, and the three-weeks RSI is set at 58.04 for Precision BioSciences Inc. [DTIL]. The present Moving Average for the last 50 days of trading for this stock 7.89, while it was recorded at 11.55 for the last single week of trading, and 7.19 for the last 200 days.
Precision BioSciences Inc. [DTIL]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Precision BioSciences Inc. [DTIL] shares currently have an operating margin of -392.14. Precision BioSciences Inc.’s Net Margin is presently recorded at -417.65.
Return on Total Capital for DTIL is now -97.83, given the latest momentum, and Return on Invested Capital for the company is -104.20. Return on Equity for this stock declined to -104.20, with Return on Assets sitting at -49.69.
Reflecting on the efficiency of the workforce at the company, Precision BioSciences Inc. [DTIL] managed to generate an average of -$466,719 per employee. Receivables Turnover for the company is 22.33 with a Total Asset Turnover recorded at a value of 0.12.Precision BioSciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.90 and a Current Ratio set at 2.90.
Precision BioSciences Inc. [DTIL]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Precision BioSciences Inc. posted -0.36/share EPS, while the average EPS was predicted by analysts to be reported at -0.48/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 25.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DTIL.
An analysis of insider ownership at Precision BioSciences Inc. [DTIL]
There are presently around $261 million, or 49.80% of DTIL stock, in the hands of institutional investors. The top three institutional holders of DTIL stocks are: CAPITAL WORLD INVESTORS with ownership of 4,062,000, which is approximately 0% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 3,753,600 shares of the stock with an approximate value of $38.4 million in DTIL stocks shares; and ARROWMARK COLORADO HOLDINGS LLC, currently with $24.8 million in DTIL stock with ownership of nearly 7.087% of the company’s market capitalization.
Positions in Precision BioSciences Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 62 institutional holders increased their position in Precision BioSciences Inc. [NASDAQ:DTIL] by around 4,254,458 shares. Additionally, 42 investors decreased positions by around 4,126,208 shares, while 30 investors held positions by with 17,094,141 shares. The mentioned changes placed institutional holdings at 25,474,807 shares, according to the latest SEC report filing. DTIL stock had 19 new institutional investments in for a total of 1,493,705 shares, while 19 institutional investors sold positions of 1,554,162 shares during the same period.